Industry experts are invited to join other industry leaders to discuss the challenges facing industry when conducting preclinical cardiovascular studies at this new forum hosted by Wake Forest Innovations.
Panel Discussions and Speaking Engagements
Barry Komm, PhD, Senior Director of Medical Affairs, Women’s Health at Pfizer. His laboratory was responsible for the development and characterization of selective estrogen receptor modulators, known as SERMs, which led to pharmacologic evaluation of SERM/estrogen combinations.
Jonathan Kimmelman, PhD, Professor of Biomedical Ethics and Director of the Studies of Translation, Ethics and Medicine (STREAM) Group, McGill University, Montreal, Canada, and corresponding author of “Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments.”
Thomas Clarkson, DVM, DACLAM, past chair of the American Heart Association Council on Arteriosclerosis, Thrombosis, and Vascular Biology, and member of the National Academy of Science’s Institute of Medicine; established an internationally known Department of Comparative Medicine at Wake Forest School of Medicine.
Jay Kaplan, PhD, Director of the Center for Comparative Medicine Research, former president of the Academy of Behavioral Medicine Research and recipient of the Irvine H. Page Arteriosclerosis Research Prize.
Larry Rudel, PhD, past chair of the American Heart Association Council on Arteriosclerosis, Thrombosis, and Vascular Biology and an internationally known researcher in the area of drug and diet effects on NHP lipoprotein metabolism.
Janice Wagner, DVM, PhD, a professor emeritus of pathology, led a highly successful research program in diabetes, lipids and cardiovascular research; published in more than 115 peer-reviewed publications.